George Scan­gos heads back to Wall Street. And he’s bring­ing along some of the best con­nec­tions in biotech

George Scan­gos’ start­up Vir Biotech­nol­o­gy has filed its plan to go pub­lic, point­ing the CEO back to Wall Street — where he’s proven a ca­pa­ble play­er.

Best known for bring­ing in his own team at Bio­gen and win­ning ac­co­lades for mak­ing Tec­fidera in­to a big block­buster in mul­ti­ple scle­ro­sis, he left well be­fore the thin pipeline proved se­vere­ly dis­ap­point­ing.

Scan­gos’ team has pen­cilled in $100 mil­lion for the fundrais­ing he has in mind, though you can be sure that with his con­nec­tions, Vir has a much larg­er fig­ure in mind. And it’s un­veil­ing the ex­act scope of an R&D al­liance with Al­ny­lam that starts with a small por­tion of cash and then swells in­to a $1.3 bil­lion smor­gas­bord of mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER